Over the past decades, the use of AD-specific biomarkers, such as cerebrospinal fluid (CSF) β-amyloid and tau, has improved the diagnostic approach previously based solely on McKhann's clinical criteria [21]. The gene discussed is MAPT; the disease is Alzheimer disease.